Aromatase inhibitors and the incidence of Parkinson disease: A population‐based cohort study

Background Current guidelines recommend the treatment of hormone receptor–positive breast cancer with aromatase inhibitors (AIs) and tamoxifen in the adjuvant setting. Some observational studies have raised concerns that tamoxifen may be associated with an increased risk of Parkinson disease (PD). H...

Ausführliche Beschreibung